Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 365

Results For "STI"

7063 News Found

KIMS Hospitals to acquire land on 99-year lease to set up new hospital at Thane
Healthcare | March 05, 2024

KIMS Hospitals to acquire land on 99-year lease to set up new hospital at Thane

The proposed hospital will have a bed capacity of 300 beds and the investment in the project is expected to be around Rs. 500 crore


Dr Mandaviya launches AYUSH-ICMR Advanced Centre for Integrated Health Research in AIIMS
Policy | March 05, 2024

Dr Mandaviya launches AYUSH-ICMR Advanced Centre for Integrated Health Research in AIIMS

Collaborative Research in AYUSH is extremely important as it bridges the gap between traditional knowledge and modern scientific research


Dr. Mandaviya addresses Governing Council Meeting of the ICMR
News | March 04, 2024

Dr. Mandaviya addresses Governing Council Meeting of the ICMR

ICMR’s budgetary allowance has increased by 4-fold in the past 10 years, showcasing our commitment towards Health Research


Briefs: SMS Pharmaceuticals and Vimta Labs
News | March 03, 2024

Briefs: SMS Pharmaceuticals and Vimta Labs

EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility


USFDA inspects Shilpa Medicare’s bio-analytical laboratory in Hyderabad
Drug Approval | March 02, 2024

USFDA inspects Shilpa Medicare’s bio-analytical laboratory in Hyderabad

This newly set up Centre for bio-analytical testing has already received European Regulatory Authority clearance recently


Aurobindo Pharma receives USFDA approval for Fingolimod Capsules, 0.5 mg
Drug Approval | March 02, 2024

Aurobindo Pharma receives USFDA approval for Fingolimod Capsules, 0.5 mg

The product will be launched in March 2024


Suven announces merger of Cohance Lifesciences
News | March 01, 2024

Suven announces merger of Cohance Lifesciences

The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals


Biocon Biologics secures US market entry date for Bmab 1200
Drug Approval | March 01, 2024

Biocon Biologics secures US market entry date for Bmab 1200

The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA


Briefs: Eugia Pharma Specialities and Eugia SEZ
News | March 01, 2024

Briefs: Eugia Pharma Specialities and Eugia SEZ

Eugia Pharma Specialities restarts production at terminally sterilized product lines